Many clinical and biomedical studies evaluate treatment effects based on multiple biomarkers that commonly consist of pre-and post-treatment measurements. Some biomarkers can show significant positive treatment effects while other biomarkers can reflect no effects or even negative effects of the treatments, giving rise to a necessity to develop methodologies that may correctly and efficiently evaluate the treatment effects based on multiple biomarkers as a whole.
Introduction
Biomarkers have been important tools in disease diagnosis, drug development and research. In the area of drug development, biomarkers' measurements can be applied to reflect drug effects, and thus are often used to compare different treatment groups. Biomarkers can show treatment effects in different magnitudes or even different directions, necessitating methodologies to examine the treatment effects based on multiple biomarkers jointly. Many studies compare treatment effects based on multiple biomarkers' measurements of independent case group and control group. This paper targets to propose methodologies that can correctly and efficiently evaluate the treatment effects based on pre-and post-treatment measurements of multiple biomarkers as a whole, and to further develop an efficient statistical testing methodology to compare independent treatment groups with paired data. One of the motivating examples in this paper is as follows. The chlorhexidine gluconate on oral bacterial pathogens study was conducted on patients admitted to the 18-bed trauma intensive care unit (TICU) of the Erie County Medical Center (ECMC) where patients were mechanically ventilated. These patients were of particular interest since they have a high risk of ventilator-associated pneumonia. While it is true that these patients are ill and thus may be more susceptible to infection, they also have the greatest need for prevention of infection. A randomized, double-blind, and placebocontrolled clinical trial tested oral topical 0.12% chlorhexidine gluconate (treatment group) and placebo with vehicle alone (control group), applied twice a day by staff nurses. Quantitation of colonization of the oral cavity by respiratory pathogens on left teeth and right teeth was measured. The aim of the study was to determine the best regimen of oral hygiene in the TICU to reduce oral colonization by potential respiratory bacterial pathogens (PRPs) . In this paper, we propose to combine the oral plaque quantification on left teeth and right teeth to maximize an AUC-type quantity based on pre-and post-treatment observations in the evaluation of the treatment effect on oral bacterial pathogens in mechanically ventilated patients.
For biomarkers whose values are measured on a continuous scale, its diagnostic performance in identifying diseased subjects is commonly assessed via receiver operating characteristic (ROC) curves, e.g., Pepe (2006) and . Suppose values of a biomarker from the diseased population and the healthy population are independent and identically distributed Bamber (1975) noted that the area under this curve is equal to Some recent biostatistical literature (e.g., Tian, 2008; Tian et al., 2012; Hauck et al., 2000) proposes to consider the quantity in the context of a generalized treatment effect, when and denote continuous outcome variables for treatment arm and control arm, respectively. Hauck et al. (200) introduced the use of in clinical trials as a statistical measurement of describing treatment effects, namely, the generalized treatment effect, and derived a method for confidence interval estimation of with normally distributed outcomes. Tian (2008) compared large sample approach, a generalized variable approach and a bootstrap approach for confidences interval estimation of generalized treatment effects in linear models. Tian et al. (2012) proposed to utilize the generalized variable method for testing equality of generalized treatment effects.
The standard ROC methodology as well as generalized treatment effects mentioned above is commonly considered with respect to case-control studies. In the case of independent populations, e.g., cases and controls, various approaches have been proposed to evaluate and compare the performance of bivariate and/or multivariate biomarkers. McClish (1987) and DeLong et al. (1988) proposed comparisons of diagnostic biomarkers based on the difference of areas under ROC curves. Wieand et al. (1989) proposed statistics for comparisons of ROC curves based on a weighted average of sensitivities. Considering the combination of multiple biomarkers as a single composite score, Pepe and Thompson (2000) , as well as Vexler et al. (2006) have considered empirical solutions to the optimal linear combinations of biomarkers in the context of nonparametric maximizations of corresponding AUCs. Su and Liu (1993) derived the optimal linear combinations yielding the largest area under the ROC curves if the values of the biomarkers in the diseased (case) and the non-diseased (control) population both follow multivariate normal distributions. We will extend to consider the generalized treatment effect of optimally combined biomarkers in a more general situation with paired data ( and are correlated). In this paper, we consider the best linear combination of pre-and post-treatment measurements of biomarkers in the sense that the AUC-type measures of treatment effects of this combination is maximized among all possible linear combinations. In a particular case, when pre-and post-treatment biomarkers' measurements are independent, the proposed method corresponds to the well-addressed result of Su and Liu's (1993) .
Additionally in this paper, to compare effects of treatments between two independent groups based on pre-and post-treatment measurements of groups of biomarkers, we propose a test statistic using the concept of the efficient maximum likelihood ratio methodology, which carries out group comparisons of AUC-type measures of the optimal linear combination of biomarkers.
Primarily, the proposed approach is applied to a randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients. Also, we demonstrate an excellent applicability of the proposed method to any relevant multiple outcomes beyond biomarker studies via a treatment study for children with ADHD and severe mood dysregulation (SMD). ADHD is the most commonly diagnosed behavioral disorder of childhood. Most children with ADHD also have at least one other developmental or behavioral problem. They may also have a psychiatric problem, such as depression or bipolar disorder. Severe mood dysregulation is a syndrome defined to capture the symptomatology of children whose diagnostic status with respect to bipolar disorder is uncertain, that is, those who have severe, nonepisodic irritability and the hyperarousal symptoms characteristic of mania but who lack the welldemarcated periods of elevated or irritable mood characteristic of bipolar disorder. For each child enrolled in the study, Depression Rating Scale (CDRS) scores and Young Mania Rating Scale (YMRS) scores were taken at the baseline and the endpoint. The objective of the study was to compare total treatment effects based on pre-and post-treatment measurements of CDRS-R and YMRS between the experimental group-based therapy program and the community psychosocial treatment (i.e., control). For more related research in this context, see Vexler et al. (2012) . In this paper, we propose to combine the measured values maximizing an AUC-type quantity based on pre-and post-treatment observations in evaluation of treatment effects in the study for children with ADHD and SMD.
This paper is organized as follows. In Section 2, we define the AUC-type measure and the estimation of the best linear combination of biomarkers. The maximum likelihood ratio test is proposed in Section 2 as well. Section 3 shows an extensive Monte Carlo study for the proposed methods. Section 4 illustrates applications to a randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients as well as a treatment study for children with ADHD and severe mood dysregulation (SMD). In Section 5, we conclude the article with remarks.
Methods
When distributions of two independent populations, say, case and control, are compared based on measurements of multiple biomarkers, it is desirable to combine the measurements of different biomarkers (e.g., Su and Liu, 1993) , since markers usually represent different aspects of diseases. Using combined scores of biomarkers can increase the diagnostic accuracy of the set of medical tests. Commonly, biomarkers' values are proposed to be combined with respect to the maximization of AUCs (e.g., Vexler et al., 2006; Liu et al., 2011) . In this paper, we derive best linear combinations of pre-and post-treatment measurements of biomarkers. The likelihood ratio test is used to compare two treatment groups (e.g., case and control) based on the AUC-type criterion computed with respect to the best linear combinations of biomarkers' values. Then, the corresponding AUC-type measure has the form of
Best linear combination
where is a standard normal cumulative distribution function. The best linear combination can be defined by maximizing the AUC-type measure, and obtaining values of , shown in the following proposition.
Proposition 2.1.1. The best linear combination coefficients , are proportional to
The proof is shown in the Appendix.
Given the best linear combination derived in Proposition 2.1.1, the maximized AUC-type measure has the form of
If biomarkers are mutually independent, that is, , and , are independent, the best linear combination coefficients are
that is, proportional to the weighted change in the mean vector , .
In a special case of independent pre-and post-treatment measurements of biomarkers, which is an analogy to the statement of a case-control study, we have the same result as that proposed by Su and Liu (1993) . The result is formalized in the following proposition.
Proposition 2.1.2. If pre-and post-treatment measurements are independent for both markers, that is, is independent of , and is independent of , the best linear combination coefficients are , . Thus, ,
The corresponding proof is outlined in the Appendix.
Thus, we propose to use the maximized AUC-type measure in the context of the best linear combinations to depict the total treatment effects based on pre-and post-treatment measurements of biomarkers. The total treatment effect has the value of .
Maximum likelihood ratio tests
In this section, we propose the maximum likelihood ratio test for comparing treatments' effects based on best linear combinations of pre-and post-treatment measurements of biomarkers. To this end, we modify the technique proposed in . 
When the parameters are unknown, we can apply the maximum likelihood ratio to be the test
The maximum likelihood estimators under have closed form solutions. The maximum loglikelihood under is
Under , in order to calculate the maximum likelihood, we carried out the numerical approach without specifying the closed forms of the estimators of the unknown parameters.
Thus, we reject the null hypothesis if , where the threshold corresponds to Type I error . Following the Wilks' Theorem (e.g., Lehmann and Romano, 1997) , under , the statistic asymptotically has a distribution. Thus, the threshold can be easily obtained from , as , . Moreover, the proposed test is asymptotically locally most powerful, e.g., see Choi et al. (1996) . 
Then the normality-based best linear combinations of biomarkers and the maximum likelihood ratio test can be used on the transformed data.
Simulation study
In this section, Monte Carlo simulations are conducted to examine the power properties of the proposed tests under different scenarios. We also compare AUC-type measures between the proposed optimal combination case and only one biomarker case.
Power and Type I error
To study the power and the Type I error of the proposed test, 2,000 samples of biomarkers' 
We consider the unequal covariance case, where
and the equal covariance case with the common covariance matrix as shown in . These parameters were chosen to reflect a real data example with values close to those in the treatment study for children with ADHD and severe mood dysregulation (SMD) introduced in Section 1. 
TABLE 2 HERE
In the same setting of parameters, Table 1 compares the Monte Carlo (MC) powers of the proposed MLR test in the context of the optimally combined two biomarkers to the powers using one biomarker alone in the equal covariance case. Table 2 depicts type I errors of the proposed MLR test with the best linear combination of two biomarkers in the equal covariance matrix case.
With the same setting of parameters, Table 3 compares the Monte Carlo powers of the proposed MLR test in the context of the optimally combined two biomarkers to the powers using one biomarker alone in the unequal covariance case. Table 5 shows the theoretical AUC-type measures and values based on 20,000 simulations as well as the Monte Carlo (MC) variance of the simulated AUC-type measures. In the scenario , the AUC type measure for X alone appears to be similar to that for the best linear combinations, suggesting that Y, in fact, adds little to the discriminating capacity of X. In the scenario , it is observed that the optimal combination provides substantially better discrimination than does X alone or Y alone. When the sample size is large, the simulated AUC-type measures with small variability are almost exactly the theoretical values as anticipated. 
Applications to data
In this section, we exemplify the proposed method with data from two clinical studies briefly described in the introduction.
Oral colonization data
A randomized, double-blind, placebo-controlled clinical trial tested oral topical 0.12% chlorhexidine gluconate or placebo , applied twice a day by staff nurses.
The paired data were constituted by two measurements of plaque on the denture surface taken from the same subjects at the baseline (day 0) and the endpoint (day 4). The goal was to determine the best regimen of oral hygiene in the TICU based on the mean plaque quantification 
ADHD data
The attention deficit-hyperactivity disorder (ADHD) and severe mood dysregulation (SMD) data were produced in Center for Children and Families at University at Buffalo to examine the feasibility and efficacy of a group-based therapy program for children with ADHD and SMD. A novel group-based therapy program was studied to treat ADHD and mood problems since most ADHD treatments have not designed to help mood problems. Children ages 7 to 12 with ADHD and SMD were randomly assigned to receive either an 11 week experimental group-based therapy program for children and parents (treatment group, ), or to community psychosocial treatment (control group, ).
FIGURE 1 HERE
Clinicians rate Children's Depression Rating Scale-revised version (CDRS-R) scores and Young Mania Rating Scale (YMRS) scores. The CDRS-R consist of 17 clinician rated items, with 14 items based on the child's self-report or reports from the parents or teachers and 3 items based on the child's nonverbal behavior during the interviews. The YMRS is an 11-item, multiple-choice diagnostic questionnaire which psychiatrists use to measure the severity of manic episodes in patients. The paired data were constituted by two measurements taken from the same subjects at the baseline (week 0) and the endpoint (week 11). The objective is to compare treatment effects with respect to CDRS-R and YMRS between the treatment group and the control group. is rejected at the 0.05 significance level. Since larger AUC values indicate better diagnostic quality. We conclude the experimental group-based therapy program is better than the community psychosocial treatment.
Conclusions
It is well known that the ROC curve is the most commonly used statistical tool to assess the quality of diagnostic biomarkers. In this paper, we constructed best linear combinations of biomarkers' measurements based on correlated data maximizing the AUC-type criterion among all possible linear combinations of the biomarker values. In a special case of independent preand post-treatment measurements of biomarkers, we showed the same result as that proposed by Su and Liu (1993) . Thus, the proposed method can be applied to both independent data as well as 
Thus, we have
It is obvious that the proposed method corresponds to Su and Liu's result. Note: "o" denotes the power of the proposed test with respect to the best linear combination of two biomarkers, while "*" denotes the power for one biomarker (X) alone based on values of , and "**" denotes the power for the other biomarker (Y) alone based on values of . Note: "o" denotes the power of the proposed test with respect to the best linear combination of two biomarkers, while "*" denotes the power for one biomarker (X) alone based on values of , and "**" denotes the power for the other biomarker (Y) alone based on values of . Note: "a" denotes the result for scenario and "b" denotes the result for scenario with the Monte Carlo (MC) variance shown in parentheses.
